Tumor therapy with a combination of anti-her2 antibodies

Abstract

The present invention provides a method for treating HER 2 positive cancer or metastasis of HER 2 positive cancer in a patient, who does not respond to a monotherapy with trastuzumab or a monotherapy with pertuzumab or to successive monotherapies with trastuzumab and pertuzumab, comprising co-administering to said patient a therapeutically-effective amount of trastuzumab and pertuzumab simultaneously or sequentially. The invention also provides A kit which comprises trastuzumab and pertuzumab and a package insert instructing the user to co-administer trastuzumab and pertuzumab to a patient suffering from HER 2 positive cancer who does not respond to a monotherapy with trastuzumab or a monotherapy with pertuzumab.

1 . A method for treating HER2 positive cancer or metastasis of HER2 positive cancer in a patient, who does not respond to a monotherapy with trastuzumab or to a monotherapy with pertuzumab or to successive monotherapies with trastuzumab and pertuzumab, comprising co-administering to said patient a therapeutically-effective amount of trastuzumab and pertuzumab simultaneously or sequentially.  
     
     
         2 . A method according to  claim 1  wherein said patient does not respond to a first-line monotherapy with trastuzumab.  
     
     
         3 . A method according to  claim 1  wherein said patient does not respond to monotherapy with trastuzumab or pertuzumab.  
     
     
         4 . A method according to  claim 1  wherein said method is for treating HER2 positive cancer in a patient.  
     
     
         5 . A method according to  claim 1  wherein said method is for treating metastasis of HER2 positive cancer in a patient and said patient does not respond to a monotherapy with trastuzumab or to a monotherapy with pertuzumab.  
     
     
         6 . A method according to  claim 1  wherein said co-administration of trastuzumab and pertuzumab comprises the administration of an initial dosage of said trastuzumab or said pertuzumab in an amount of from about 1 μg/kg to about 50 mg/kg.  
     
     
         7 . A method according to  claim 1  wherein said co-administration of trastuzumab and pertuzumab comprises the administration of an initial dosage of said trastuzumab or said pertuzumab in an amount of from about 0.05 mg/kg to about 10 mg/kg.  
     
     
         8 . A method according to  claim 1  wherein said HER2 positive cancer is a primary tumor.  
     
     
         9 . A method according to  claim 1  wherein said HER2 positive cancer is a locally advanced cancer or a metastatic cancer.  
     
     
         10 . A method according to  claim 1  wherein said HER2 positive cancer is selected from the group consisting of: breast cancer; lung cancer; colon cancer; and prostate cancer.  
     
     
         11 . A method according to  claim 1  wherein said HER2 positive cancer is breast cancer.  
     
     
         12 . A method according to  claim 1  wherein said metastasis is a metastasis of the lung.  
     
     
         13 . A kit which comprises trastuzumab and pertuzumab and a package insert instructing the user to co-administer trastuzumab and pertuzumab to a patient suffering from HER2 positive cancer who does not respond to a monotherapy with trastuzumab or a monotherapy with pertuzumab.  
     
     
         14 . A kit according to  claim 12  wherein said patient does not respond to a first-line monotherapy with trastuzumab.